The people at novineon CRO have a common understanding of quality, diligence and responsibility. The are specialized in various scientific fields such as medicine, natural and engineering sciences. Thus, an interdisciplinary and competent team is at your disposal for every project.
Prof. Dr. med. Marc O. Schurr
+49-(0)7071 / 98 979-130
has substantial professional experience in the global healthcare industry. This concerns not only Research & Development, but also the market side. He attended medical school in Tuebingen, Germany, including stays in the US and Italy, and took his doctoral degree following relevant research in the area of medical technologies. After graduation from medical school he attended business education at the St. Galler Management Seminar. Prior to foundation of novineon Prof. Schurr has been working in medical research and management consulting. Prof. Dr. med. Marc O. Schurr has been conducting clinical evaluations since 2003. He has been clinical trial investigator since 2007.
Dr. rer. nat. Marion Fehlker
Director of Operations, authorized representative
+49-(0)7071 / 98 979-124
studied chemistry with biochemistry as a major subject at the University of Stuttgart. Subsequently, she did a doctorate in biology with the main focus on biochemistry/molecular biology at the Charité in Berlin. From 2005 – 2009 she worked as a post-doc in biomedical research at the Max-Delbrück-Centrum in Berlin, mainly studying the molecular biology of colorectal carcinoma. Since July 2010, Dr. Marion Fehlker is responsible for clinical evaluations at novineon CRO GmbH. Since 2013, she is certified “Manager Regulatory Affairs Medical Devices International”. Dr, Marion Fehlker has been trained by CenTrial (Tuebingen) in the planning of clinical trials. Since 2016, she is “Director of Operations” of the service division of novineon CRO GmbH.
Dr. rer. nat. Timo Weiland
Director Research & Development, authorized representative
+49-(0)7071 / 98 979-123
studied biology at the University of Konstanz and gained his doctoral degree at the Department of Biochemical Pharmacology in 2007. There, he continued conducting research in the field of hepatic cell death and cytoprotective signalling pathways until 2008. Afterwards, he continued his work at the University Hospital Tuebingen within the Collaborative Research Centre SFB 773 “Therapy Resistance of Solid Tumours”.
In September 2011, Dr. Weiland joined novineon CRO GmbH, where he is responsible for clinical evaluations. In 2013, he successfully completed the Certificate Course “Medical Device Regulatory Affairs” at the Centre for Further Education and Transfer of Knowledge (ZWW) at the University of Augsburg. Dr. rer. nat. Timo Weiland is certified as clinical data manager.
Dr. rer. nat. Marc Brändle
+49-(0)7071 / 98 979-136
did his Bachelor’s and Master’s degree in molecular medicine at the University of Tuebingen. From 2011 to 2012, within the course of the 4-year BACHELOR PLUS studies with integrated flexibility window, he was enrolled in human medicine at the Medical University of Innsbruck. From 2014 to 2018, he did his doctoral studies in biochemistry at the Interfaculty Institute of Biochemistry (IFIB) in Tuebingen with focus on the molecular biology of Non-Hodgkin Lymphoma. Since July 2018, Dr. Marc Brändle has been responsible for clinical evaluations of medical devices at novineon CRO GmbH.
Julia Ehmann, M.Sc.
+49-(0)7071 / 98 979-126
studied Bioengineering with a focus on biopharmaceutical and mechanical process engineering at the Karlsruhe Institute of Technology (KIT). She worked as a visiting researcher at the Center for Microbial Diseases and Immunity Research at the University of British Columbia in Vancouver on the characterization of the multi-resistant bacteria P. aeruginosa regarding biofilm formation and cytotoxicity. During her master thesis at the Institute of Microstructure Technology Julia Ehmann investigated the nanostructuring of titanium by thermal and hydrothermal technologies for the optimization of medical implants. Julia Ehmann has been trained by CenTrial (Tuebingen) in the planning of clinical trials. Since November 2017, Julia Ehmann is mainly responsible for clinical evaluations and FDA-submissions at novineon CRO GmbH.
Dr. rer. nat. Benedikt Fabry
+49-(0)7071 / 98 979-127
studied Biology with a focus on plant physiology, virology and pharmacology at the University of Hohenheim. He conducted his Diploma at the Institute of Plant Physiology and Biotechnology at the University of Hohenheim. During his PhD project he studied the influence of the protein Torsin1A on the development of the central nervous system at the Institute of Medical Genetics and Applied Genomics of the Eberhard Karls University Tübingen, where he worked on further scientific projects after his graduation. Dr. rer. nat. Benedikt Fabry has been trained by CenTrial (Tuebingen) in the planning and conducting of clinical trials. Since February 2018, he is responsible for clinical evaluations at novineon CRO GmbH.
Dr. rer. nat. Maria Kiel
+49-(0)7071 / 98 979-134
studied biology with a focus on neurobiology at the Eberhard Karls University Tübingen. She proceeded to her doctorate at the Graduate Training Center of Neuroscience, International Max Planck Research School at the Eberhard Karls University of Tübingen. During her PhD research, Dr. Maria Kiel investigated the representation of abstract quantities and decisions by individual cells in the prefrontal cortex. After completing her PhD thesis, Dr. Maria Kiel worked in medical publishing. Her working activities included research, medical writing and project management. Afterwards Dr. Maria Kiel worked in technical marketing for measurement technology. In June 2020 Dr. Maria Kiel joined novineon CRO GmbH, where she is responsible for clinical evaluations.
Sebastian Lorscheid, M.Sc.
+49-(0)7071 / 98 979-137
studied molecular biology with special focus on medical biology and biochemistry at the Westfälische Hochschule. For his master thesis he moved to the Interfaculty Institut of Biochemistry (IFIB) in Tuebingen, where he analyzed the regulation of murine macrophage functionality during inflammation. Sebastian Lorscheid continued his work at the IFIB to receive a PhD degree in biochemistry, which he will complete in 2020. Topic of this thesis are the progression and regulation of psoriasis in different mouse models. Since May 2020, Sebastian Lorscheid has been responsible for clinical evaluations at novineon CRO GmbH.
Iweta Metzger, M.Sc.
+49-(0)7071 / 98 979-128
studied Molecular Nutritional Science with special focus on experimental research, genetics and molecular mechanisms at the University of Hohenheim. For her master thesis at the Institute of Animal Science, Iweta Metzger investigated the effect of metformin on the intestinal microbial community of mice. In an experimental project at the University of Vienna she conducted research on the aging-associated modification of intestinal homeostasis and barrier function. Iweta Metzger specialized in the legal aspects of food law, pharmaceutical and medical technological regulations during her semester in Vienna. Since February 2019, she has been responsible for clinical evaluations at novineon CRO GmbH.
Elke Krapp, Dipl.-Ing. (BA)
+49-(0)7071 / 98 979-122
studied radiation-protection at the Berufsakademie Mannheim (type of a university of applied sciences) in combination with the nuclear research center in Karlsruhe. Afterwards, she worked in the clinic for radiotherapy and nuclear medicine in Karlsruhe. Later she worked as study nurse and study coordinator in the university eye hospital in Tuebingen. Elke Krapp has been study assistant for clinical trials since 2003. Since 2011 she has supported novineon CRO GmbH in compilation of clinical evaluations.
Dr. rer. nat. Stefanie Meese
+49-(0)7071 / 98 979-129
studied Biology with a focus on immunology, parasitology and virology at the Eberhard Karls University Tuebingen. She gained her PhD in the field of malaria research within the framework of the international research training group on Functional Molecular Infection Epidemiology at the Institute of Tropical Medicine and International Health of the Charité in Berlin. During her PhD she investigated the impact of genetic factors on the in vitro growth of the malaria parasite Plasmodium falciparum and the innate immune response towards P. falciparum-infected erythrocytes. Within the scope of her scientific research she contributed to several publications. Dr. rer. nat. Stefanie Meese has been trained by CenTrial (Tuebingen) in the planning and conducting of clinical trials. Since March 2016, Dr. Stefanie Meese is mainly responsible for clinical evaluations at novineon CRO GmbH.
Dr. rer. nat. Sabrina Rohrer
+49-(0)7071 / 98 979-133
studied biology with special emphasis on microbiology, genetics and paleoanthropology at the Eberhard Karls University Tübingen. Subsequently, Dr. Sabrina Rohrer gained her PhD within the Research Training Group 1708 “Bacterial Survival Strategies” at the department for microbiology/biotechnology of the Eberhard Karls University Tübingen. During her PhD work, she investigated the role of the lysolipin either as an antibiotic or a signaling molecule. Additionally, Dr. Sabrina Rohrer attended a professional seminar “Life Science Management” at the ATV GmbH, Munich. Dr. rer. nat. Sabrina Rohrer has been trained by CenTrial (Tuebingen) in the planning and conducting of clinical trials. Since April 2017, she has been responsible for clinical evaluations and clinical trials at novineon CRO GmbH. Since 2018, Dr. Sabrina Rohrer is also certified as “study manager in clinical trials (IHK)”.
Nicole Zabel, M.Sc.
+49-(0)7071 / 98 979-149
studied biochemistry with special focus on clinical chemistry and molecular cell biology in tumor development at the Technische Universität München. For her master thesis at the Institute of Biochemistry and Technical Biochemistry at the University of Stuttgart, Nicole Zabel analyzed the degradation of artificial misfolded proteins of the endoplasmic reticulum in baker’s yeast. From 2013 – 2019, she continued her work to receive a PhD degree, which will be completed in summer 2020. Since February 2020, Nicole Zabel has been responsible for clinical evaluations at novineon CRO GmbH.